BE2016C012I2 - - Google Patents

Download PDF

Info

Publication number: BE2016C012I2
Authority: BE; Belgium
Prior art keywords: sup; whereinr; andx; cooet; coome
Prior art date: 2000-02-23

Application number

BE2016C012C

Other languages

English (en)

Original Assignee

Ucb Biopharma Sprl

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-23

Filing date

2016-03-09

Publication date

2020-01-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9886259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2016C012(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-03-09 Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl

2020-01-30 Publication of BE2016C012I2 publication Critical patent/BE2016C012I2/fr

Links

HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 abstract 1
125000000262 haloalkenyl group Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Addiction (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Otolaryngology (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrrole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

BE2016C012C 2000-02-23 2016-03-09 BE2016C012I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0004297.8A GB0004297D0 (en)	2000-02-23	2000-02-23	2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
EP01925354A EP1265862B1 (fr)	2000-02-23	2001-02-21	Derives de 2-oxo-1-pyrrolidine, procedes de preparation et utilisations desdits derives

Publications (1)

Publication Number	Publication Date
BE2016C012I2 true BE2016C012I2 (fr)	2020-01-30

Family

ID=9886259

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2016C012C BE2016C012I2 (fr)	2000-02-23	2016-03-09

Country Status (43)

Country	Link
US (12)	US6713635B2 (fr)
EP (8)	EP1265862B1 (fr)
JP (5)	JP4121744B2 (fr)
KR (4)	KR100816185B1 (fr)
CN (5)	CN1179944C (fr)
AT (5)	ATE282592T1 (fr)
AU (5)	AU778510B2 (fr)
BE (1)	BE2016C012I2 (fr)
BG (4)	BG65923B1 (fr)
BR (2)	BR0108657A (fr)
CA (2)	CA2401048C (fr)
CO (2)	CO5271667A1 (fr)
CU (2)	CU23201A3 (fr)
CY (3)	CY1105517T1 (fr)
CZ (3)	CZ304420B6 (fr)
DE (5)	DE60140222D1 (fr)
DK (3)	DK1452524T3 (fr)
EG (1)	EG24375A (fr)
ES (5)	ES2334998T3 (fr)
FR (1)	FR16C1001I2 (fr)
GB (1)	GB0004297D0 (fr)
HK (2)	HK1052695B (fr)
HU (4)	HUP0300196A3 (fr)
IL (5)	IL150842A0 (fr)
IS (8)	IS2119B (fr)
LT (1)	LTC1265862I2 (fr)
LU (1)	LU92993I2 (fr)
ME (1)	MEP6109A (fr)
MX (2)	MXPA02008056A (fr)
MY (4)	MY127149A (fr)
NL (1)	NL300815I2 (fr)
NO (6)	NO324485B1 (fr)
NZ (1)	NZ520448A (fr)
PL (3)	PL212197B1 (fr)
PT (2)	PT1452524E (fr)
RO (2)	RO121597B1 (fr)
RS (2)	RS50455B (fr)
RU (5)	RU2291860C3 (fr)
SA (2)	SA01220027B1 (fr)
SI (1)	SI1265862T1 (fr)
TW (2)	TW200626544A (fr)
WO (2)	WO2001062726A2 (fr)
ZA (2)	ZA200205671B (fr)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7365093B2 (en) *	1994-08-19	2008-04-29	Abbott Laboratories	Endothelin antagonists
GB0004297D0 (en) *	2000-02-23	2000-04-12	Ucb Sa	2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6686477B2 (en)	2000-09-29	2004-02-03	Eastman Chemical Company	Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same
WO2002067931A1 (fr) *	2001-02-23	2002-09-06	Johns Hopkins University	Traitement des tics, tremblements et troubles afferents
JP4334344B2 (ja) *	2001-08-10	2009-09-30	ユセベファルマソシエテアノニム	オキソピロリジン化合物、当該化合物の調製、並びにレベチラセタム及び類似体の製造におけるその化合物の使用
DE60218193T2 (de) *	2001-10-08	2007-11-22	Ucb S.A.	Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
WO2003032981A1 (fr)	2001-10-16	2003-04-24	Memory Pharmaceuticals Corporation	Derives 4-(4-alcoky-3-hydroxyphenyle)-2-pyrrolidone utilises en tant qu'inhibiteurs de la pde4 pour le traitement de syndromes neurologiques
AU2003242538A1 (en) *	2002-05-14	2003-11-11	Ucb, S.A.	Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
DE602004023051D1 (de) *	2003-01-13	2009-10-22	Ucb Pharma Sa	Hydrierungskatalysatoren
CN1802352A (zh) *	2003-02-03	2006-07-12	特瓦制药工业有限公司	制备左乙拉西坦的方法
ES2214147B1 (es)	2003-02-28	2005-10-01	Farma-Lepori S.A.	Procedimiento de obtencion de un agente antiepileptico.
TR200503397T1 (tr) *	2003-03-18	2007-03-21	Hetero Drugs Limited	Levetirasetam'ın yeni kristal formları.
RU2232578C1 (ru) *	2003-04-10	2004-07-20	Ахапкина Валентина Ивановна	Вещество, обладающее антидепрессивной активностью
US7696198B2 (en)	2003-04-16	2010-04-13	Memory Pharmaceuticals Corporation	Phosphodiesterase 4 inhibitors
US7034051B2 (en) *	2003-08-28	2006-04-25	Adolor Corporation	Fused bicyclic carboxamide derivatives and methods of their use
WO2005023763A1 (fr) *	2003-09-05	2005-03-17	Ranbaxy Laboratories Limited	Procede de preparation de levetiracetam pur
EP1667967B1 (fr) *	2003-09-24	2012-08-01	UCB Pharma, S.A.	Procede de preparation des derives de 2-oxo-1-pyrrolidin
CA2546970C (fr)	2003-12-02	2011-04-26	Ucb, S.A.	Derives d'imidazole, leurs procedes de preparation et leurs utilisations
CN1964942A (zh) *	2004-06-11	2007-05-16	Ucb股份有限公司	通过分子内烯丙基化制备2－氧代－1－吡咯烷衍生物的方法
CN1972904B (zh) *	2004-06-21	2011-02-02	沃尼尔·朗伯有限责任公司	普瑞巴林和相关化合物的制备
US7427601B2 (en) *	2004-06-24	2008-09-23	Schwarz Pharma Ag	Method for treating tremor
WO2006044955A1 (fr) *	2004-10-20	2006-04-27	Memory Pharmaceuticals Corporation	Inhibiteurs de la phosphodiéstérase 4
CA2488325C (fr) *	2004-11-22	2010-08-24	Apotex Pharmachem Inc.	Methode de synthese amelioree du (s)-alpha-ethyl-2-oxo-1-pyrrolidine-acetamide et du (r)-alpha-ethyl-2-oxo-1-pyrroldine-acetamide
US8178533B2 (en)	2005-06-01	2012-05-15	Ucb Pharma, S.A.	2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
EP1731149A1 (fr) *	2005-06-08	2006-12-13	Ucb S.A.	Utilisation de Brivaracetam pour le traitement de maladies caracterisées par l'épilepsie myoclonique progressive
CN101263113B (zh) *	2005-09-15	2012-06-13	Ucb医药有限公司	4-取代的-吡咯烷-2-酮及其用途
JP2007153755A (ja) *	2005-12-01	2007-06-21	Gifu Univ	プロリン類縁体
US8076493B2 (en) *	2005-12-07	2011-12-13	Ucb Pharma, S.A.	3-carboxy-2-oxo-1-pyrrolidine derivatives and their uses
US8338621B2 (en)	2005-12-21	2012-12-25	Ucb S.A.	Process for the preparation of 2-oxo-1-pyrrolidine derivatives
LV13630B (en) *	2006-03-16	2007-12-20	Olainfarm As	Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone
EP2041084B1 (fr) *	2006-06-08	2013-11-06	UCB Pharma, S.A.	Co-cristaux de pyrrolidinones
EA019757B1 (ru) *	2006-06-15	2014-06-30	ЮСиБи ФАРМА ГМБХ	Фармацевтическая композиция с синергетическим противосудорожным эффектом
EP2051696A2 (fr) *	2006-08-18	2009-04-29	Morton Grove Pharmaceuticals, Inc.	Compositions liquides stables de lévétiracétam et procédés
GEP20125425B (en) *	2006-10-18	2012-03-26	Pfizer Prod Inc	Biaryl ether urea compounds
US8828665B2 (en)	2007-02-16	2014-09-09	Ark Diagnostics, Inc.	Compounds and methods for use in detecting gabapentin
EP2152262A2 (fr) *	2007-04-27	2010-02-17	UCB Pharma, S.A.	Nouveaux dérivés hétérocycliques utilisés pour le traitement de maladies du snc
US20090082422A1 (en) *	2007-09-26	2009-03-26	Protia, Llc	Deuterium-enriched levetiracetam
DK2273975T3 (da) *	2008-03-03	2014-06-30	Ucb Pharma Sa	Farmaceutiske opløsninger, fremgangsmåde til fremstilling og terapeutiske anvendelser
US7741327B2 (en) *	2008-04-16	2010-06-22	Hoffmann-La Roche Inc.	Pyrrolidinone glucokinase activators
WO2010002869A1 (fr) *	2008-07-01	2010-01-07	Concert Pharmaceuticals, Inc.	Derives de 2-oxo-1-pyrrolidine
EP2147911A1 (fr)	2008-07-24	2010-01-27	ZaCh System S.p.A.	Procédé de préparation de lévétiracetam
JP4644881B2 (ja) *	2008-09-19	2011-03-09	高砂香料工業株式会社	ルテニウム錯体の製造方法
EP2346500B1 (fr)	2008-10-16	2017-05-17	The Johns Hopkins University	Procédés et compositions pour l amélioration d'une fonction cognitive
US8168756B2 (en)	2008-10-24	2012-05-01	Ark Diagnostics, Inc.	Levetiracetam immunoassays
WO2010054009A1 (fr) *	2008-11-07	2010-05-14	Novabay Pharmaceuticals, Inc.	Compositions antimicrobiennes d'oxazolidinone, d'hydantoïne et d'imidazolidinone
KR101788804B1 (ko) *	2008-11-18	2017-10-20	유씨비 파마, 에스.에이.	２―옥소―１―피롤리딘 유도체를 포함하는 연장 방출 제형
KR101689688B1 (ko) *	2008-11-18	2016-12-26	유씨비 파마, 에스.에이.	２옥소１피롤리딘 유도체를 포함하는 지연 방출형 제형
FR2939311A1 (fr) *	2008-12-08	2010-06-11	Oreal	Utilisation d'un derive diester de pyrrolidinone 4-carboxy comme solvant dans les compositions cosmetiques ; compositions cosmetiques les contenant
EP2393483B1 (fr)	2009-02-09	2017-06-28	UCB Biopharma SPRL	Compositions pharmaceutiques comportant du brivaracetam
US8846411B2 (en) *	2009-06-11	2014-09-30	Microgenics Corporation	Derivatives, reagents, and immunoassay for detecting levetiracetam
WO2011015349A2 (fr)	2009-08-07	2011-02-10	Ucb Pharma, S.A.	Méthodes damélioration de la fonction cognitive
US7939676B2 (en)	2009-09-17	2011-05-10	Zach System S.P.A.	Process for the preparation of levetiracetam
US8487591B1 (en)	2009-12-31	2013-07-16	Cirrus Logic, Inc.	Power control system with power drop out immunity and uncompromised startup time
PL389364A1 (pl)	2009-10-23	2011-04-26	Uniwersytet Jagielloński	Nowe zastosowanie pochodnych 2-pirolidonu
TW201118103A (en)	2009-10-23	2011-06-01	Ucb Pharma Sa	2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives
EP2533645B1 (fr)	2010-02-09	2016-07-27	The Johns Hopkins University	Procédés et compositions pour améliorer la fonction cognitive
FR2961098A1 (fr)	2010-06-09	2011-12-16	Oreal	Composition comprenant au moins une 2-pyrrolidone fonctionnalisee en position 4 par un acide carboxylique ou amide, et au moins un colorant direct ou un pigment pour la teinture des fibres keratiniques
FR2961101B1 (fr)	2010-06-09	2013-01-25	Oreal	Composition comprenant au moins une 2-pyrrolidone fonctionnalisee par un radical ester ou amide, et au moins un pigment ou un colorant direct pour la teinture des matieres keratiniques
FR2961099B1 (fr)	2010-06-09	2012-06-15	Oreal	Derives de 2-pyrrolidone fonctionnalisee par un radical ester, acide ou amide, la composition cosmetique les comprenant et leur utilisation pour le conditionnement des matieres keratiniques
US8466297B2 (en)	2010-11-01	2013-06-18	Milan Soukup	Manufacturing process for (S)-Pregabalin
AU2011328993B2 (en)	2010-11-15	2017-03-02	Agenebio, Inc.	Pyridazine derivatives, compositions and methods for treating cognitive impairment
EP2672822A4 (fr) *	2011-02-09	2014-08-27	Univ Johns Hopkins	Procédés et composition pour améliorer la fonction cognitive
PL2699581T3 (pl)	2011-04-18	2016-05-31	Ucb Biopharma Sprl	Pochodne 2-okso-1-imidazolidynyloimidazotiadiazolu
JP6162125B2 (ja)	2011-09-30	2017-07-12	タフツ・ユニバーシティ	神経変性障害を処置するためのウリジン二リン酸誘導体、組成物および方法
RU2632659C2 (ru) *	2011-12-27	2017-10-09	Байо-Фарм Солюшнс Ко., Лтд.	Фенилкарбаматные соединения для применения в предупреждении или лечении эпилепсии
TW201408293A (zh) *	2012-07-05	2014-03-01	Merz Pharma Gmbh & Co Kgaa	(r)-苯基披喇瑟盪於治療疾病相關疲勞之用途
TW201408294A (zh) *	2012-07-05	2014-03-01	Merz Pharma Gmbh & Co Kgaa	(r)-苯基披喇瑟盪於治療帕金森氏症之用除
US9163055B2 (en)	2012-09-28	2015-10-20	Tufts University	Methods for treating glaucoma using uridine diphosphate derivatives
US10154988B2 (en)	2012-11-14	2018-12-18	The Johns Hopkins University	Methods and compositions for treating schizophrenia
DK2928865T3 (en)	2012-12-07	2018-06-18	Merck Sharp & Dohme	BIOCATALYTIC TRANSAMINATION PROCEDURE
WO2014087367A2 (fr) *	2012-12-09	2014-06-12	Mahesh Kandula	Compositions et procédés pour le traitement de maladies neurologiques et de leurs complications associées
WO2014113717A1 (fr)	2013-01-18	2014-07-24	Ark Diagnostics, Inc.	Immunodosages de viroconazole
WO2014126861A1 (fr)	2013-02-13	2014-08-21	Ark Diagnostics, Inc.	Dosages immunologiques du posaconazole
PL2968385T3 (pl)	2013-03-13	2019-05-31	Univ Tufts	Pochodne nukleozydów urydynowych, kompozycje i sposoby zastosowania
US10138265B2 (en)	2013-03-13	2018-11-27	Tufts University	Uridine nucleoside derivatives, compositions and methods of use
US10806717B2 (en)	2013-03-15	2020-10-20	The Johns Hopkins University	Methods and compositions for improving cognitive function
CN103342672B (zh) *	2013-07-02	2015-12-23	扬州大学	取代吡咯烷-2-酮的新合成方法
JP6465634B2 (ja) *	2013-12-05	2019-02-06	株式会社日本触媒	環状アミド基含有重合体
JP6453632B2 (ja) *	2013-12-05	2019-01-16	株式会社日本触媒	環状アミドアクリレート含有組成物およびその製造方法
EP4032889B1 (fr)	2013-12-20	2026-05-06	Agenebio, Inc.	Dérivés de benzodiazépine, compositions et méthodes de traitement de déficience cognitive
ME03518B (fr)	2014-01-21	2020-04-20	Janssen Pharmaceutica Nv	Combinaisons comprenant des modulateurs allostériques positifs de sous-type 2 de récepteurs glutamatergiques métabotropes et leur utilisation
PL3096790T3 (pl)	2014-01-21	2020-01-31	Janssen Pharmaceutica, N.V.	Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
CN104098497B (zh) *	2014-06-17	2016-04-13	王庚禹	一种新的酰胺类化合物
WO2016075082A1 (fr)	2014-11-10	2016-05-19	Sandoz Ag	Amination réductrice stéréosélective d'aldéhydes alpha-chiraux au moyen d'ω-transaminases pour la synthèse de précurseurs de la prégabaline et du brivaracétam
WO2016131947A1 (fr)	2015-02-20	2016-08-25	Ucb Biopharma Sprl	Traitement d'association
CN108689968B (zh) *	2015-05-25	2020-09-15	苏州鹏旭医药科技有限公司	两种化合物及其制备方法和在合成布瓦西坦中的用途
CN106365986B (zh) *	2015-07-21	2019-01-08	苏州鹏旭医药科技有限公司	化合物及其制备方法和在合成布瓦西坦中的用途
JP6872500B2 (ja)	2015-05-25	2021-05-19	エステベ・キミカ・ソシエダッド・アノニマＥｓｔｅｖｅＱｕｉｍｉｃａ，Ｓ．Ａ．	ブリバラセタムを製造する方法
US11384104B2 (en)	2015-06-19	2022-07-12	Centurion Biopharma Corporation	Delivery systems for controlled drug release
EP3310785B1 (fr)	2015-06-19	2024-11-20	Agenebio, Inc.	Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive
WO2017076737A1 (fr)	2015-11-03	2017-05-11	Ucb Biopharma Sprl	Procédé continu de préparation de brivaracétam
HRP20211518T1 (hr)	2015-11-03	2021-12-24	UCB Biopharma SRL	Postupak priprave brivaracetama
CN106748748B (zh) *	2015-11-10	2021-08-24	成都国为生物医药有限公司	一种布瓦西坦的制备方法及其中间体
EP3397253A1 (fr)	2015-12-30	2018-11-07	Adamas Pharmaceuticals, Inc.	Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques
CN105646319B (zh) *	2015-12-30	2018-05-18	佛山市隆信医药科技有限公司	一种布瓦西坦的制备方法
EP3452447A4 (fr)	2016-05-03	2019-12-18	The Regents of The University of California	Inhibiteurs de synthèse de protéines médiée par des ires
RU2629117C1 (ru) *	2016-06-14	2017-08-24	Сизов Владимир Владимирович	Способ получения 4-замещенного 2-[2-оксо-1-пирролидинил] ацетамида
CN107513031B (zh) *	2016-06-16	2022-08-02	上海医药集团股份有限公司	一种2-氧代-1-吡咯烷手性衍生物的制备方法
US20180170941A1 (en)	2016-12-19	2018-06-21	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2018136792A1 (fr)	2017-01-20	2018-07-26	The Regents Of The University Of California	Inhibiteurs du domaine n-terminal du récepteur d'androgène
CN106866483A (zh) *	2017-02-05	2017-06-20	苏州鹏旭医药科技有限公司	布瓦西坦的晶型c及其制备方法
WO2018141276A1 (fr) *	2017-02-05	2018-08-09	苏州鹏旭医药科技有限公司	Forme cristalline a de l'intermédiaire de brivaracétam et son procédé de préparation, forme cristalline c de brivaracétam et son procédé de préparation
CN108503610B (zh)	2017-02-24	2019-09-13	北京艾百诺医药股份有限公司	一种光学纯的(r)-4-正丙基-二氢呋喃-2(3h)-酮的制备方法
CN108658831B (zh) *	2017-03-30	2021-11-05	江苏豪森药业集团有限公司	2-氧代-1-吡咯烷衍生物或其盐的制备方法
WO2018200517A1 (fr)	2017-04-24	2018-11-01	Tesaro, Inc.	Procédés de fabrication de niraparib
IL321754A (en)	2017-06-30	2025-08-01	Univ California	Compositions and methods for modulating hair growth
KR20240017986A (ko)	2017-09-26	2024-02-08	더 리전트 오브 더 유니버시티 오브 캘리포니아	암 치료를 위한 조성물 및 방법
CN107721896A (zh) *	2017-10-19	2018-02-23	丽珠集团新北江制药股份有限公司	一种布瓦西坦的中间体的制备方法
CN107793342A (zh) *	2017-10-19	2018-03-13	丽珠集团新北江制药股份有限公司	一种布瓦西坦的制备方法
BR112020009836A2 (pt)	2017-11-30	2020-10-13	Centurion Biopharma Corporation	pró-drogas de ligação a albumina de derivados de auristatina e
IL305268A (en)	2017-11-30	2023-10-01	Centurion Biopharma Corp	Maytansinoid-based drug delivery systems
US11708329B2 (en)	2018-01-30	2023-07-25	The Regents Of The University Of California	Inhibitors of the WNT/beta-catenin pathway
CN108147988B (zh) *	2018-02-13	2020-10-02	扬州奥锐特药业有限公司	一种高手性纯度内酰胺化合物的制备方法
CN108530402B (zh) *	2018-04-10	2020-06-26	浙江工业大学	一种(R)-3-丙基-γ-丁内酯的制备方法
EP3566760A1 (fr) *	2018-05-07	2019-11-13	Universite Libre De Bruxelles	Procédé pour la nucléation de cristaux dans un tube capillaire à partir d'une solution
CN112088160B (zh)	2018-05-08	2023-07-04	Ucb生物制药有限责任公司	1-咪唑并噻二唑并-2h-吡咯-5-酮衍生物
AU2019288382B2 (en)	2018-06-19	2024-07-25	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN110615744B (zh) *	2018-06-20	2023-01-06	上海朴颐化学科技有限公司	一种布瓦西坦中间体及其制备方法
US20210122771A1 (en)	2018-06-29	2021-04-29	The Regents Of The University Of California	New molecular tweezers against neurological disorders and viral infections
RU2699669C1 (ru) *	2018-07-04	2019-09-09	Общество С Ограниченной Ответственностью "Валента - Интеллект"	Новые составы N-карбамоилметил-4-фенил-2-пирролидона
WO2020023917A1 (fr)	2018-07-27	2020-01-30	California Institute Of Technology	Inhibiteurs de cdk et leurs utilisations
ES3066008T3 (en)	2018-10-17	2026-05-11	Univ California	Prodrugs of alpha-ketoglutarate, alpha-ketobutyrate, alpha-ketoisovalerate, and alpha-ketoisohexanoate, and uses thereof
EP3699173A1 (fr)	2018-10-18	2020-08-26	California Institute of Technology	Pyrrolidines, pipérazines et diazépanes disubstitués par gem, compositions et leurs procédés de fabrication
EP3873912B1 (fr)	2018-10-31	2026-03-25	Intocell, Inc.	Dérivés de benzodiazépine hétérocycliques fusionnés et leurs utilisations
JP2022510363A (ja)	2018-12-04	2022-01-26	メティスファーマシューティカルズアクチェンゲゼルシャフト	（ｒ）－２－（２－オキソピロリジン－１－イル）ブタンアミドと（ｓ）－２－（２－オキソピロリジン－１－イル）ブタンアミドを非ラセミ比で含む相乗的組成物
WO2020176386A2 (fr)	2019-02-25	2020-09-03	The Regents Of The University Of California	Procédés de fragmentation de liaison carbone-carbone
CN109932442A (zh) *	2019-03-04	2019-06-25	成都美域高制药有限公司	一种布瓦西坦异构体的检测方法
EP3947387B1 (fr)	2019-03-25	2024-10-23	California Institute Of Technology	Inhibiteurs de prmt5 et leurs utilisations
JP2022534704A (ja)	2019-06-04	2022-08-03	ヘイガーバイオサイエンシズ，エルエルシー	オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法
CN110357752A (zh) *	2019-08-15	2019-10-22	中国工程物理研究院化工材料研究所	一种快速制备均匀包覆含能材料的方法
RU2732245C1 (ru) *	2019-08-30	2020-09-14	Ооо "Валента-Интеллект"	Новые составы n-карбамоилметил-4-фенил-2-пирролидона для лечения и профилактики ожирения
CN110551050A (zh) *	2019-09-02	2019-12-10	南通大学	一种2-[3’-(N-Boc-吡咯基)]-苯甲酸的合成方法
US10781170B1 (en)	2019-10-21	2020-09-22	Divi's Laboratories Ltd.	Process for preparing Brivaracetam
US12649736B2 (en)	2019-12-20	2026-06-09	The Regents Of The University Of California	Synthesis of compounds to promote hair growth
WO2021142132A1 (fr)	2020-01-07	2021-07-15	The Trustees Of Princeton University	Compositions et procédés pour le traitement d'une maladie par manipulation du métabolisme de la sérine
WO2021142221A1 (fr)	2020-01-10	2021-07-15	The Regents Of The University Of California	Compositions et méthodes de traitement de maladies neurodégénératives
US20230174460A1 (en)	2020-04-21	2023-06-08	President And Fellowes Of Harvard College	Afmt analogs and their use in methods of treating parkinson's disease
LV15614A (lv)	2020-07-30	2022-02-20	Latvijas Organiskās Sintēzes Institūts	2-(2-okso-3-pirolin-1-il)acetamīdi kā pretkrampju līdzekļi
EP4192838A1 (fr)	2020-08-10	2023-06-14	Dana-Farber Cancer Institute, Inc.	Inhibiteurs à petites molécules pyrimidine-thiéno-pyridine tricycliques fusionnées de la protéase 28 spécifique de l'ubiquitine
EP4192811A1 (fr)	2020-08-10	2023-06-14	Dana-Farber Cancer Institute, Inc.	3-amino-4-méthylbenzènesulfonamides substitués en tant qu'inhibiteurs à petites molécules de la protéase 28 spécifique à l'ubiquitine
US20230265082A1 (en)	2020-08-10	2023-08-24	Dana-Farber Cancer Institute, Inc.	Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
CN116782894A (zh) *	2020-10-06	2023-09-19	D.E.肖研究有限责任公司	作为Kv1.3钾Shaker通道阻断剂的内酰胺化合物
US20240083839A1 (en)	2020-10-07	2024-03-14	The Regents Of The University Of California	Compositions and methods for treating neurodegenerative diseases and disorders
US12570620B2 (en)	2020-10-23	2026-03-10	Dana-Farber Cancer Institute, Inc.	Covalent inhibitors of creatine kinase (CK) and uses thereof for treating and preventing cancer
US20240058344A1 (en)	2020-12-18	2024-02-22	Cornell University	Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
WO2022140289A1 (fr)	2020-12-21	2022-06-30	Cornell University	Système d'administration de médicaments à liaison peptidique
WO2022150574A1 (fr)	2021-01-08	2022-07-14	Cornell University	Inhibiteurs de la lipoamide déshydrogénase de mycobacterium tuberculosis
US11400074B1 (en)	2021-02-01	2022-08-02	Divi's Laboratories Ltd.	Enzymatic process for the preparation of (2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl]butyric acid and its conversion into brivaracetam
US12559456B2 (en)	2021-02-03	2026-02-24	Suzhou Brighthope Pharma Tech Co., Ltd	Method for preparing levetiracetam and intermediates thereof
US11384050B1 (en)	2021-02-03	2022-07-12	Vitaworks Ip, Llc	Method for preparing levetiracetam and intermediates thereof
CN114948953A (zh) *	2021-06-29	2022-08-30	四川大学华西医院	一种杂原子取代芳香类化合物及其盐的用途
CN113511994B (zh) *	2021-08-16	2023-03-21	江苏八巨药业有限公司	一种左乙拉西坦的制备方法
EP4463462A4 (fr)	2022-01-14	2025-06-25	Annexon, Inc.	Inhibiteurs de facteurs du complément et utilisations associées
CA3252219A1 (fr)	2022-02-15	2023-08-24	Rs Oncology, Llc	Composés inspirés par le thiostrepton pour le traitement du cancer et préparation connexe
CN114634437B (zh) *	2022-03-29	2023-05-30	武汉氟本氘合新材料科技有限公司	一种布瓦西坦的简易制备方法
US11884623B2 (en)	2022-05-23	2024-01-30	Divi's Laboratories Ltd.	Process for the preparation of (R)-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam
WO2023250157A1 (fr)	2022-06-24	2023-12-28	Cornell University	Inhibiteurs de mycobacterium tuberculosis lipoamide déshydrogénase
JP2025525415A (ja)	2022-07-13	2025-08-05	アストラゼネカ・アクチエボラーグ	Ｐｃｓｋ９阻害剤およびその使用方法
EP4572852A1 (fr)	2022-08-19	2025-06-25	Agenebio, Inc.	Dérivés de benzoazépine, compositions et méthodes de traitement de déficience cognitive
EP4582412A4 (fr) *	2022-08-31	2026-01-21	Univ Korea Res & Bus Found	Dérivé de gamma lactame chiral ou sel pharmaceutiquement acceptable de celui-ci, et sa méthode de préparation
US20260225046A1 (en)	2023-02-02	2026-08-06	Osmoses Inc.	Norbornyl benzocyclobutene ladder polymer composite membranes for fluid separation
CN116041240B (zh)	2023-02-17	2024-04-09	扬州奥锐特药业有限公司	布立西坦中间体的不对称催化氢化合成方法
EP4431086A1 (fr)	2023-03-16	2024-09-18	Adalvo Limited	Composition pharmaceutique comprenant du (2s)-2--[(4r)-2-oxo-4-propyltétrahydro-1h-pyrrol-1-yl!butanamide
US12590059B2 (en)	2023-03-28	2026-03-31	Suzhou Brighthope Pharmatech Co., Ltd	Process for the production of levetiracetam
WO2025078883A2 (fr)	2023-05-06	2025-04-17	Prepaire Labs Limited	Composé organique (oxime) pour lutter contre des agents chimiques de guerre
US12528770B2 (en)	2023-06-12	2026-01-20	Suzhou Brighthope Pharmatech Co., Ltd.	Process for the production of levetiracetam and intermediates thereof
IL327035A (en)	2023-09-18	2026-05-01	Flagship Pioneering Innovations Vii Llc	Ionizable lipidoid compositions and their medical uses
WO2025072751A1 (fr)	2023-09-29	2025-04-03	Battelle Memorial Institute	Compositions de nanoparticules polymères pour l'expression in vivo de polypeptides
AU2024349841A1 (en)	2023-09-29	2026-04-09	Battelle Memorial Institute	Polymer nanoparticle compositions for non-viral gene delivery
KR20260113064A (ko)	2023-11-14	2026-07-21	플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨	이온화 가능한 리피도이드 조성물 및 이의 치료적 용도
WO2025231452A1 (fr)	2024-05-02	2025-11-06	Martinez Montemayor Michelle	Dérivés de peroxyde d'ergostérol et leurs utilisations
WO2026030679A1 (fr)	2024-08-01	2026-02-05	Osmoses Inc.	Membranes polymères à fibres creuses pour séparation de fluide
WO2026060616A1 (fr)	2024-09-20	2026-03-26	Fulcrum Therapeutics, Inc.	Inhibiteurs de phénothiazine et de phénoxazine calmoduline et leurs procédés d'utilisation
US20260090998A1 (en)	2024-10-02	2026-04-02	Battelle Memorial Institute	Methods of using polymer nanoparticle compositions for treating a disease
WO2026089782A2 (fr)	2024-10-22	2026-04-30	Osmoses Inc.	Procédé de collecte de gaz hélium par exploitation d'hydrogène géologique exempt de gaz à effet de serre
WO2026107178A1 (fr)	2024-11-13	2026-05-21	Cornell University	Profilage par affinité globale d'interactions moléculaires à l'aide d'un enrichissement compétitif

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE92031C (fr)
DD92031A (fr) *
US2836599A (en) *	1957-03-07	1958-05-27	Aerojet General Co	Nu-(carboxyalkyl) dinitro lactams
GB1309692A (en) *	1970-02-13	1973-03-14	Ucb Sa	N-substituted lactams
GB1039113A (en)	1964-08-06	1966-08-17	Ucb Sa	New n-substituted lactams
US4008281A (en)	1973-12-03	1977-02-15	Monsanto Company	Asymmetric catalysis
HU177239B (hu)	1974-10-15	1981-08-28	Monsanto Co	Eljárás N-acetamido-L-alanin-származékok előállítására α-acetamido-akrilsav-származékok aszimmetrikus katalitikus hídrogénezésével
DE3361609D1 (en) *	1982-03-24	1986-02-06	Prodes Sa	New n-((2-oxo-1-pyrrolidinyl)acetyl)piperazines, the methods of producing such new compounds and their salts as well as pharmaceutical preparations for therapeutic use containing these compounds or salts
EP0089901B1 (fr) *	1982-03-24	1987-05-13	Prodes S.A.	Esters de l'acide 2-oxo-1-pyrrolidineacétique, procédés de préparation et compositions thérapeutiques les contenant
GB8412358D0 (en) *	1984-05-15	1984-06-20	Ucb Sa	Pharmaceutical composition
GB8412357D0 (en) *	1984-05-15	1984-06-20	Ucb Sa	Pharmaceutical composition
CN1015542B (zh) *	1984-05-15	1992-02-19	尤西比公司	(R)-α-乙基-2-氧代-1-吡咯烷乙酰胺的制备方法
JPS60166692A (ja)	1984-09-28	1985-08-29	Kazuo Achinami	新規不斉還元試薬
CH666891A5 (de) *	1985-11-26	1988-08-31	Lonza Ag	4-alkoxy-2-oxo-pyrrolidin-1-yl-essigsaeure-c(1)-c(4)-alkylester, deren herstellung und verwendung.
DE3719873A1 (de) *	1987-06-13	1988-12-29	Basf Ag	Verfahren zur herstellung von itaconsaeurediestern und itaconsaeure
JPH0757758B2 (ja)	1988-10-24	1995-06-21	高砂香料工業株式会社	ルテニウム―ホスフィン錯体
GB8827389D0 (en)	1988-11-23	1988-12-29	Ucb Sa	Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide
SK279285B6 (sk) *	1991-05-02	1998-09-09	Daiichi Pharmaceutical Co.	Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
US5171892A (en)	1991-07-02	1992-12-15	E. I. Du Pont De Nemours And Company	Chiral phospholanes via chiral 1,4-diol cyclic sulfates
GB9319732D0 (en)	1993-09-24	1993-11-10	Ucb Sa	Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
EP0645135A1 (fr) *	1993-09-29	1995-03-29	Solco Basel AG	Composition antisolaire contenant du hémodialysate
JPH1180027A (ja) *	1997-09-12	1999-03-23	Dai Ichi Seiyaku Co Ltd	向知性薬
TW544311B (en) *	1998-08-06	2003-08-01	Daiichi Seiyaku Co	Therapeutic or preventive agent for intractable epilepsies
CZ20001055A3 (cs) *	1998-10-02	2000-08-16	Dupont Pharmaceuticals Company	Nové laktamové inhibitory metaloproteázy
CA2392879C (fr)	1999-12-01	2005-03-29	Ucb, S.A.	Derive de pyrrolidine acetamide seul ou combine pour traiter des affections du snc
GB0004297D0 (en) *	2000-02-23	2000-04-12	Ucb Sa	2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6686477B2 (en)	2000-09-29	2004-02-03	Eastman Chemical Company	Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same

2000
- 2000-02-23 GB GBGB0004297.8A patent/GB0004297D0/en not_active Ceased
2001
- 2001-02-21 PL PL359388A patent/PL212197B1/pl not_active IP Right Cessation
- 2001-02-21 RO ROA200201141A patent/RO121597B1/ro unknown
- 2001-02-21 HU HU0300196A patent/HUP0300196A3/hu unknown
- 2001-02-21 AU AU73896/01A patent/AU778510B2/en not_active Ceased
- 2001-02-21 ES ES04007878T patent/ES2334998T3/es not_active Expired - Lifetime
- 2001-02-21 BR BR0108657-0A patent/BR0108657A/pt not_active IP Right Cessation
- 2001-02-21 AU AU5214401A patent/AU5214401A/xx active Pending
- 2001-02-21 ME MEP-61/09A patent/MEP6109A/xx unknown
- 2001-02-21 DE DE60140222T patent/DE60140222D1/de not_active Expired - Lifetime
- 2001-02-21 WO PCT/EP2001/001992 patent/WO2001062726A2/fr not_active Ceased
- 2001-02-21 DK DK04007878.4T patent/DK1452524T3/da active
- 2001-02-21 DE DE60143493T patent/DE60143493D1/de not_active Expired - Lifetime
- 2001-02-21 HU HU0500902A patent/HU230270B1/hu active Protection Beyond IP Right Term
- 2001-02-21 MY MYPI20010763A patent/MY127149A/en unknown
- 2001-02-21 DE DE60119397T patent/DE60119397T2/de not_active Expired - Lifetime
- 2001-02-21 PL PL365159A patent/PL210121B1/pl unknown
- 2001-02-21 DK DK04007733T patent/DK1447399T3/da active
- 2001-02-21 EP EP01925354A patent/EP1265862B1/fr not_active Expired - Lifetime
- 2001-02-21 HU HU0204526A patent/HU229514B1/hu unknown
- 2001-02-21 RS YUP-632/02A patent/RS50455B/sr unknown
- 2001-02-21 CN CNB018055079A patent/CN1179944C/zh not_active Expired - Fee Related
- 2001-02-21 HK HK03104935.7A patent/HK1052695B/zh not_active IP Right Cessation
- 2001-02-21 EP EP04008270A patent/EP1477478B1/fr not_active Expired - Lifetime
- 2001-02-21 CA CA002401048A patent/CA2401048C/fr not_active Expired - Fee Related
- 2001-02-21 KR KR1020027010960A patent/KR100816185B1/ko not_active Expired - Lifetime
- 2001-02-21 EP EP05012174A patent/EP1577296A1/fr not_active Withdrawn
- 2001-02-21 MX MXPA02008056A patent/MXPA02008056A/es active IP Right Grant
- 2001-02-21 EP EP04030940A patent/EP1577295A1/fr not_active Withdrawn
- 2001-02-21 PL PL380061A patent/PL213669B1/pl unknown
- 2001-02-21 EP EP04007878A patent/EP1452524B1/fr not_active Expired - Lifetime
- 2001-02-21 ES ES04008270T patent/ES2355140T3/es not_active Expired - Lifetime
- 2001-02-21 RS YUP-631/02A patent/RS50454B/sr unknown
- 2001-02-21 EG EG20010172A patent/EG24375A/xx active
- 2001-02-21 ES ES01940256T patent/ES2231501T3/es not_active Expired - Lifetime
- 2001-02-21 CO CO01013822A patent/CO5271667A1/es not_active Application Discontinuation
- 2001-02-21 ES ES04007733T patent/ES2264060T3/es not_active Expired - Lifetime
- 2001-02-21 RU RU2002124522A patent/RU2291860C3/ru active
- 2001-02-21 RO ROA200201076A patent/RO121559B1/ro unknown
- 2001-02-21 CN CNA2005100999524A patent/CN1740151A/zh active Pending
- 2001-02-21 DE DE60107216T patent/DE60107216T2/de not_active Expired - Lifetime
- 2001-02-21 KR KR1020027010984A patent/KR100759145B1/ko not_active Expired - Fee Related
- 2001-02-21 CN CNB2005100713086A patent/CN1303066C/zh not_active Expired - Fee Related
- 2001-02-21 WO PCT/EP2001/001956 patent/WO2001064637A1/fr not_active Ceased
- 2001-02-21 IL IL15084201A patent/IL150842A0/xx active IP Right Grant
- 2001-02-21 NZ NZ520448A patent/NZ520448A/en not_active IP Right Cessation
- 2001-02-21 ES ES01925354T patent/ES2248307T3/es not_active Expired - Lifetime
- 2001-02-21 HK HK03104916.0A patent/HK1052516B/zh not_active IP Right Cessation
- 2001-02-21 EP EP01940256A patent/EP1263727B1/fr not_active Expired - Lifetime
- 2001-02-21 CZ CZ2002-2850A patent/CZ304420B6/cs not_active IP Right Cessation
- 2001-02-21 DK DK01925354T patent/DK1265862T3/da active
- 2001-02-21 CA CA002401033A patent/CA2401033C/fr not_active Expired - Lifetime
- 2001-02-21 IL IL15075701A patent/IL150757A0/xx not_active IP Right Cessation
- 2001-02-21 DE DE60113514T patent/DE60113514T2/de not_active Expired - Lifetime
- 2001-02-21 CZ CZ2005-763A patent/CZ304702B6/cs unknown
- 2001-02-21 AT AT01940256T patent/ATE282592T1/de active
- 2001-02-21 CN CNA2005100999539A patent/CN1740150A/zh active Pending
- 2001-02-21 PT PT04007878T patent/PT1452524E/pt unknown
- 2001-02-21 CO CO01013823A patent/CO5280059A1/es not_active Application Discontinuation
- 2001-02-21 SI SI200130451T patent/SI1265862T1/sl unknown
- 2001-02-21 KR KR1020057016175A patent/KR100720784B1/ko not_active Expired - Lifetime
- 2001-02-21 AT AT04007733T patent/ATE325093T1/de active
- 2001-02-21 AT AT04007878T patent/ATE445597T1/de active
- 2001-02-21 RU RU2006125756/04A patent/RU2355680C2/ru not_active IP Right Cessation
- 2001-02-21 BR BRPI0108664A patent/BRPI0108664B8/pt not_active IP Right Cessation
- 2001-02-21 MX MXPA02008206A patent/MXPA02008206A/es active IP Right Grant
- 2001-02-21 KR KR1020057016174A patent/KR100681580B1/ko not_active Expired - Fee Related
- 2001-02-21 RU RU2002124865/04A patent/RU2292336C2/ru not_active IP Right Cessation
- 2001-02-21 CN CNB018054455A patent/CN1208319C/zh not_active Expired - Lifetime
- 2001-02-21 CZ CZ20022849A patent/CZ20022849A3/cs unknown
- 2001-02-21 MY MYPI20052965A patent/MY140593A/en unknown
- 2001-02-21 JP JP2001561734A patent/JP4121744B2/ja not_active Expired - Lifetime
- 2001-02-21 MY MYPI20010775A patent/MY138966A/en unknown
- 2001-02-21 PT PT04007733T patent/PT1447399E/pt unknown
- 2001-02-21 EP EP05013657A patent/EP1604979A1/fr not_active Withdrawn
- 2001-02-21 US US10/204,275 patent/US6713635B2/en not_active Expired - Fee Related
- 2001-02-21 AU AU2001252144A patent/AU2001252144C1/en not_active Expired
- 2001-02-21 AT AT01925354T patent/ATE304999T1/de active
- 2001-02-21 MY MYPI20053631A patent/MY139420A/en unknown
- 2001-02-21 EP EP04007733A patent/EP1447399B9/fr not_active Expired - Lifetime
- 2001-02-21 JP JP2001563480A patent/JP4081275B2/ja not_active Expired - Fee Related
- 2001-02-21 AT AT04008270T patent/ATE488500T1/de not_active IP Right Cessation
- 2001-03-13 TW TW095112074A patent/TW200626544A/zh unknown
- 2001-03-13 TW TW095112075A patent/TW200626545A/zh unknown
- 2001-04-01 SA SA01220027A patent/SA01220027B1/ar unknown
- 2001-04-24 SA SA01220078A patent/SA01220078B1/ar unknown
2002
- 2002-02-21 US US10/204,266 patent/US6784197B2/en not_active Expired - Lifetime
- 2002-07-16 ZA ZA200205671A patent/ZA200205671B/en unknown
- 2002-07-16 IS IS6472A patent/IS2119B/is unknown
- 2002-07-22 IL IL150842A patent/IL150842A/en unknown
- 2002-07-22 ZA ZA200205837A patent/ZA200205837B/en unknown
- 2002-07-23 IS IS6481A patent/IS2176B/is unknown
- 2002-08-14 BG BG107004A patent/BG65923B1/bg unknown
- 2002-08-20 BG BG107016A patent/BG65783B1/bg unknown
- 2002-08-20 BG BG109297A patent/BG109297A/en unknown
- 2002-08-22 NO NO20023997A patent/NO324485B1/no active Protection Beyond IP Right Term
- 2002-08-22 NO NO20023995A patent/NO324051B1/no not_active IP Right Cessation
- 2002-08-26 CU CU20020180A patent/CU23201A3/es unknown
- 2002-08-26 CU CU20020181A patent/CU23293B7/es not_active IP Right Cessation
2003
- 2003-07-01 US US10/609,544 patent/US6858740B2/en not_active Expired - Fee Related
- 2003-10-28 US US10/694,090 patent/US6806287B2/en not_active Expired - Lifetime
- 2003-10-28 US US10/693,917 patent/US6911461B2/en not_active Expired - Lifetime
2004
- 2004-04-15 US US10/824,345 patent/US6969770B2/en not_active Expired - Fee Related
2005
- 2005-01-04 US US11/028,039 patent/US7217826B2/en not_active Expired - Fee Related
- 2005-01-27 US US11/043,176 patent/US7358276B2/en not_active Expired - Lifetime
- 2005-01-27 US US11/043,145 patent/US20050171187A1/en not_active Abandoned
- 2005-02-09 IL IL166768A patent/IL166768A/en not_active IP Right Cessation
- 2005-02-17 AU AU2005200718A patent/AU2005200718B2/en not_active Ceased
- 2005-02-17 AU AU2005200717A patent/AU2005200717B2/en not_active Ceased
- 2005-06-29 IS IS7921A patent/IS7921A/is unknown
- 2005-06-29 IS IS7920A patent/IS7920A/is unknown
- 2005-06-29 IS IS7922A patent/IS2754B/is unknown
- 2005-06-29 IS IS7923A patent/IS7923A/is unknown
- 2005-06-29 IS IS7919A patent/IS7919A/is unknown
- 2005-06-29 IS IS7918A patent/IS7918A/is unknown
- 2005-07-27 JP JP2005217442A patent/JP4938259B2/ja not_active Expired - Lifetime
- 2005-07-27 NO NO20053645A patent/NO20053645L/no not_active Application Discontinuation
- 2005-07-27 NO NO20053644A patent/NO20053644L/no not_active Application Discontinuation
- 2005-07-27 JP JP2005217433A patent/JP2006022107A/ja active Pending
- 2005-08-09 IL IL170181A patent/IL170181A/en active Protection Beyond IP Right Term
- 2005-08-11 RU RU2005125569/04A patent/RU2005125569A/ru not_active Application Discontinuation
- 2005-08-12 RU RU2005125645/04A patent/RU2005125645A/ru not_active Application Discontinuation
- 2005-09-16 BG BG109297A patent/BG65803B1/bg unknown
2006
- 2006-07-28 CY CY20061101045T patent/CY1105517T1/el unknown
2007
- 2007-04-10 JP JP2007102379A patent/JP4769756B2/ja not_active Expired - Fee Related
- 2007-12-13 US US12/000,512 patent/US7692028B2/en not_active Expired - Fee Related
2010
- 2010-01-11 CY CY20101100031T patent/CY1109718T1/el unknown
- 2010-02-17 US US12/656,808 patent/US8034958B2/en not_active Expired - Fee Related
2011
- 2011-08-31 US US13/222,477 patent/US8492416B2/en not_active Expired - Fee Related
2016
- 2016-03-08 NO NO2016005C patent/NO2016005I2/no unknown
- 2016-03-09 BE BE2016C012C patent/BE2016C012I2/fr unknown
- 2016-03-11 LU LU92993C patent/LU92993I2/fr unknown
- 2016-04-13 HU HUS1600017C patent/HUS1600017I1/hu unknown
- 2016-05-04 LT LTPA2016013C patent/LTC1265862I2/lt unknown
- 2016-05-25 FR FR16C1001C patent/FR16C1001I2/fr active Active
- 2016-05-27 NL NL300815C patent/NL300815I2/nl unknown
- 2016-06-30 CY CY2016022C patent/CY2016022I1/el unknown
2023
- 2023-06-20 NO NO2023025C patent/NO2023025I1/no unknown

Also Published As

Publication number	Publication date
FR16C1001I2 (fr)	2017-02-03
DE60113514T2 (de)	2006-05-18
PT1452524E (pt)	2010-01-18
CY2016022I2 (el)	2016-10-05
JP2007182459A (ja)	2007-07-19
RS50454B (sr)	2010-03-02
RU2355680C2 (ru)	2009-05-20
US20040116507A1 (en)	2004-06-17
DK1447399T3 (da)	2006-08-28
DE60107216D1 (de)	2004-12-23
CY1105517T1 (el)	2010-07-28
US20040192757A1 (en)	2004-09-30
NO20053645L (no)	2002-10-22
RU2005125645A (ru)	2007-02-20
US7358276B2 (en)	2008-04-15
RO121559B1 (ro)	2007-11-30
HU0500902D0 (en)	2005-12-28
BG65923B1 (bg)	2010-05-31
HK1052516A1 (en)	2003-09-19
HK1052695B (zh)	2005-05-06
ZA200205837B (en)	2003-11-04
IS6481A (is)	2002-07-23
CO5271667A1 (es)	2003-04-30
JP2003523996A (ja)	2003-08-12
BR0108657A (pt)	2003-04-29
RU2291860C3 (ru)	2017-11-16
CA2401033A1 (fr)	2001-08-30
HUP0300196A3 (en)	2005-10-28
ATE304999T1 (de)	2005-10-15
EP1577296A1 (fr)	2005-09-21
TW200626545A (en)	2006-08-01
US20040087646A1 (en)	2004-05-06
EG24375A (en)	2009-03-19
RO121597B1 (ro)	2007-12-28
SA01220027B1 (ar)	2006-09-19
HK1052695A1 (en)	2003-09-26
RS50455B (sr)	2010-03-02
PL210121B1 (pl)	2011-12-30
NO2023025I1 (no)	2023-06-20
WO2001062726A3 (fr)	2002-01-17
EP1263727B1 (fr)	2004-11-17
AU5214401A (en)	2001-09-03
KR20050090090A (ko)	2005-09-12
US20120035239A1 (en)	2012-02-09
NO20053644L (no)	2002-10-22
CA2401033C (fr)	2008-07-29
AU2001252144B2 (en)	2005-04-28
HUS1600017I1 (hu)	2020-02-28
MY140593A (en)	2009-12-31
WO2001062726A2 (fr)	2001-08-30
CZ304702B6 (cs)	2014-09-03
EP1477478A2 (fr)	2004-11-17
CN1740150A (zh)	2006-03-01
EP1452524B1 (fr)	2009-10-14
MXPA02008056A (es)	2004-08-12
LTC1265862I2 (lt)	2023-09-11
NO20023997D0 (no)	2002-08-22
DE60107216T2 (de)	2005-11-03
US20030120080A1 (en)	2003-06-26
IS7923A (is)	2005-06-29
NL300815I2 (fr)	2016-07-27
NO324485B1 (no)	2007-10-29
EP1577295A1 (fr)	2005-09-21
DE60143493D1 (de)	2010-12-30
IL150842A0 (en)	2003-02-12
US20050159475A1 (en)	2005-07-21
IS7921A (is)	2005-06-29
HUP0204526A2 (hu)	2003-04-28
JP4081275B2 (ja)	2008-04-23
LTPA2016013I1 (lt)	2016-05-25
US8034958B2 (en)	2011-10-11
EP1604979A1 (fr)	2005-12-14
HU229514B1 (en)	2014-01-28
IS2119B (is)	2006-06-15
IL170181A (en)	2010-11-30
IS2754B (is)	2011-09-15
CA2401048C (fr)	2009-01-20
RU2006125756A (ru)	2008-01-27
EP1477478A3 (fr)	2004-11-24
IS7919A (is)	2005-06-29
KR20050091112A (ko)	2005-09-14
JP2006022107A (ja)	2006-01-26
JP4769756B2 (ja)	2011-09-07
US6784197B2 (en)	2004-08-31
AU2005200717A1 (en)	2005-03-17
FR16C1001I1 (fr)	2016-07-01
US7692028B2 (en)	2010-04-06
NZ520448A (en)	2004-03-26
PT1447399E (pt)	2006-09-29
BG109297A (en)	2006-06-30
EP1447399B1 (fr)	2006-05-03
AU778510B2 (en)	2004-12-09
IS7918A (is)	2005-06-29
EP1447399A1 (fr)	2004-08-18
BG65783B1 (bg)	2009-11-30
IS6472A (is)	2002-07-16
AU2001252144C1 (en)	2008-03-20
BG107004A (bg)	2003-04-30
US20050171188A1 (en)	2005-08-04
CN1740151A (zh)	2006-03-01
SI1265862T1 (sl)	2006-02-28
US6911461B2 (en)	2005-06-28
US20030040631A1 (en)	2003-02-27
AU2005200718A1 (en)	2005-03-17
DE60119397T2 (de)	2007-04-19
KR100759145B1 (ko)	2007-09-14
CU23201A3 (es)	2007-04-06
ATE325093T1 (de)	2006-06-15
NO324051B1 (no)	2007-08-06
IL150757A0 (en)	2003-02-12
RU2291860C2 (ru)	2007-01-20
ZA200205671B (en)	2003-11-10
CN1179944C (zh)	2004-12-15
LU92993I2 (fr)	2016-05-11
NO20023997L (no)	2002-10-22
CZ304420B6 (cs)	2014-04-30
US7217826B2 (en)	2007-05-15
HUP0204526A3 (en)	2005-03-29
ES2355140T3 (es)	2011-03-23
ES2248307T3 (es)	2006-03-16
CN1404469A (zh)	2003-03-19
IL166768A (en)	2010-04-15
DE60113514D1 (de)	2005-10-27
US20080097109A1 (en)	2008-04-24
ME00595B (fr)	2011-12-20
CU23293B7 (es)	2008-06-30
AU7389601A (en)	2001-09-12
DE60119397D1 (de)	2006-06-08
ATE445597T1 (de)	2009-10-15
YU63202A (sh)	2005-09-19
RU2002124865A (ru)	2004-01-10
CZ20022849A3 (cs)	2003-02-12
CN1680314A (zh)	2005-10-12
PL212197B1 (pl)	2012-08-31
US6806287B2 (en)	2004-10-19
KR100816185B1 (ko)	2008-03-21
ES2231501T3 (es)	2005-05-16
JP2006022108A (ja)	2006-01-26
NO20023995L (no)	2002-10-21
IL150842A (en)	2008-06-05
CZ20022850A3 (cs)	2003-02-12
KR20020075926A (ko)	2002-10-07
CY1109718T1 (el)	2014-08-13
PL365159A1 (en)	2004-12-27
BG65803B1 (bg)	2009-12-31
HUP0300196A2 (hu)	2003-06-28
GB0004297D0 (en)	2000-04-12
DK1265862T3 (da)	2006-01-30
PL359388A1 (en)	2004-08-23
US6969770B2 (en)	2005-11-29
CN1208319C (zh)	2005-06-29
ES2264060T3 (es)	2006-12-16
JP2003528828A (ja)	2003-09-30
PL213669B1 (pl)	2013-04-30
KR100720784B1 (ko)	2007-05-23
EP1477478B1 (fr)	2010-11-17
US20040092576A1 (en)	2004-05-13
MEP6109A (en)	2011-12-20
CN1303066C (zh)	2007-03-07
US6713635B2 (en)	2004-03-30
IS7920A (is)	2005-06-29
WO2001064637A1 (fr)	2001-09-07
MY127149A (en)	2006-11-30
US6858740B2 (en)	2005-02-22
US20050171187A1 (en)	2005-08-04
BRPI0108664B1 (pt)	2016-07-26
US8492416B2 (en)	2013-07-23
HU230270B1 (hu)	2015-11-30
YU63102A (sh)	2005-09-19
CN1404470A (zh)	2003-03-19
ATE282592T1 (de)	2004-12-15
IS7922A (is)	2005-06-29
MXPA02008206A (es)	2004-04-05
MY139420A (en)	2009-09-30
ATE488500T1 (de)	2010-12-15
CO5280059A1 (es)	2003-05-30
DE60140222D1 (de)	2009-11-26
CY2016022I1 (el)	2016-10-05
EP1263727A1 (fr)	2002-12-11
JP4121744B2 (ja)	2008-07-23
EP1265862B1 (fr)	2005-09-21
DK1452524T3 (da)	2010-03-01
NO20023995D0 (no)	2002-08-22
EP1452524A1 (fr)	2004-09-01
NO2016005I1 (no)	2016-03-08
BG107016A (en)	2003-04-30
KR100681580B1 (ko)	2007-02-09
CA2401048A1 (fr)	2001-09-07
HK1052516B (zh)	2006-02-10
AU2005200718B2 (en)	2007-05-24
EP1265862A2 (fr)	2002-12-18
IL166768A0 (en)	2006-01-15
US20100222576A1 (en)	2010-09-02
TW200626544A (en)	2006-08-01
JP4938259B2 (ja)	2012-05-23
NO2016005I2 (no)	2016-03-08
AU2005200717B2 (en)	2007-05-17
RU2005125569A (ru)	2007-02-20
ES2334998T3 (es)	2010-03-18
KR20020075927A (ko)	2002-10-07
RU2292336C2 (ru)	2007-01-27
MY138966A (en)	2009-08-28
SA01220078B1 (ar)	2006-10-29
IS2176B (is)	2006-12-15
BRPI0108664B8 (pt)	2021-05-25
EP1447399B9 (fr)	2006-10-18
BR0108664A (pt)	2003-04-29